Unlock stock picks and a broker-level newsfeed that powers Wall Street.

3 US Penny Stocks With Market Caps Under $800M

In This Article:

As U.S. equities face a challenging period, with the Dow and S&P 500 on track for their worst month since April, investors are increasingly exploring alternative investment avenues. Penny stocks, despite their somewhat outdated name, continue to attract attention as they represent smaller or less-established companies that might offer value amidst market volatility. By focusing on those with strong financials and potential for growth, investors can uncover opportunities in this niche segment of the market.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

Inter & Co (NasdaqGS:INTR)

$4.25

$1.87B

★★★★☆☆

QuantaSing Group (NasdaqGM:QSG)

$3.08

$104.78M

★★★★★★

BAB (OTCPK:BABB)

$0.86

$6.25M

★★★★★★

Pangaea Logistics Solutions (NasdaqCM:PANL)

$4.89

$229.35M

★★★★★☆

ZTEST Electronics (OTCPK:ZTST.F)

$0.25

$9.2M

★★★★★★

Golden Growers Cooperative (OTCPK:GGRO.U)

$4.50

$67.38M

★★★★★★

BTCS (NasdaqCM:BTCS)

$2.54

$44.07M

★★★★★★

Smith Micro Software (NasdaqCM:SMSI)

$1.45

$25.72M

★★★★★☆

CBAK Energy Technology (NasdaqCM:CBAT)

$1.07

$96.23M

★★★★★☆

Safe Bulkers (NYSE:SB)

$3.57

$381.2M

★★★★☆☆

Click here to see the full list of 731 stocks from our US Penny Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Anebulo Pharmaceuticals

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing treatments for unintentional cannabis poisoning and related conditions in the United States, with a market cap of $44.09 million.

Operations: Anebulo Pharmaceuticals, Inc. does not report any revenue segments as it is currently a clinical-stage biotechnology company.

Market Cap: $44.09M

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology firm, is pre-revenue and focuses on developing treatments for cannabis-related conditions. The company has no debt and maintains short-term assets of US$2 million against liabilities of US$569.2K. Despite its unprofitability, Anebulo has reduced losses by 29.9% annually over the past five years. Recent financing through a private placement raised nearly US$15 million, potentially extending its cash runway beyond the initial two months forecasted based on free cash flow estimates. However, the stock remains highly volatile with weekly volatility higher than 75% of U.S. stocks.